Regulus Therapeutics
RGLS
#7005
Rank
โ‚ฌ0.48 B
Marketcap
7,03ย โ‚ฌ
Share price
0.00%
Change (1 day)
407.54%
Change (1 year)

Regulus Therapeutics (RGLS) - Total debt

Total debt on the balance sheet as of March 2025 : โ‚ฌ1.2 Million

According to Regulus Therapeutics's latest financial reports the company's total debt is โ‚ฌ1.2 Million. A companyโ€™s total debt is the sum of all current and non-current debts.

Regulus Therapeutics - Total debt on balance sheet (from 2011 to 2025)

Total debt by year

Year Total debt Change
2024-12-31โ‚ฌ0.26 M-87.82%
2023-12-31โ‚ฌ2.16 M-63.08%
2022-12-31โ‚ฌ5.85 M-6.5%
2021-12-31โ‚ฌ6.26 M65.53%
2020-12-31โ‚ฌ3.78 M-71.04%
2019-12-31โ‚ฌ13.06 M-9.86%
2018-12-31โ‚ฌ14.48 M-12.46%
2017-12-31โ‚ฌ16.55 M-12.08%
2016-12-31โ‚ฌ18.82 M
2014-12-31โ‚ฌ19.23 M135.55%
2013-12-31โ‚ฌ8.16 M6.61%
2012-12-31โ‚ฌ7.66 M-0.51%
2011-12-31โ‚ฌ7.7 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Sanofi
SNY
โ‚ฌ20.56 B 1,704,475.30%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
โ‚ฌ5.66 B 469,364.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚ฌ40.58 B 3,364,568.09%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
โ‚ฌ25.09 B 2,080,485.30%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
โ‚ฌ20.54 B 1,703,247.61%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sangamo Therapeutics
SGMO
โ‚ฌ21.89 M 1,714.70%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
โ‚ฌ1.10 B 91,148.39%๐Ÿ‡บ๐Ÿ‡ธ USA